NR 566 MIDTERM EXAM 2026/2027 | ADVANCED NURSING QUESTIONS & ANSWERS…
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 566 Midterm Exam
2026/2027 | Advanced
Nursing Questions &
Answers | Exam-Focused
Review (Rationales)
Verified Answers Exam Ready With Rationales 84 QUESTIONS
DOCUMENT OVERVIEW
This document provides 84 questions with correct answers and detailed rationales, serving
as an exam-focused review for advanced nursing. It covers a broad range of clinical nursing
topics, offering students a comprehensive tool for study, course review, and certification
preparation.
TOPICS
Respiratory Infections & Treatments Q1–Q18
Antibiotic Pharmacology & Patient Education Q19–Q35
Antifungal & Anthelmintic Agents Q36–Q42
HIV & Antiretroviral Therapy Q43–Q49
Dermatology & Ophthalmic Agents Q50–Q67
Weight Management Pharmacology Q68–Q84
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 84
Common CAP pathogens
RESPONSE
S. Pneumoniae (most common)
H. Influenzae (smokers/COPD)
P. Aeruginosa (CF)
RATIONALE
Community-acquired pneumonia (CAP) is most frequently caused by *Streptococcus
pneumoniae*. *Haemophilus influenzae* is a common pathogen in individuals with underlying
respiratory conditions like COPD or smoking history, while *Pseudomonas aeruginosa* is a
significant cause in patients with cystic fibrosis. The findings in the stem align with this choice,
making it the best-supported option.
Q2 QUESTION 2 OF 84
CAP first line treatment
RESPONSE
Macrolides, Doxycyline, Amoxicillin
RATIONALE
Community-acquired pneumonia (CAP) first-line pharmacotherapy targets common bacterial
pathogens. Empiric treatment often includes macrolides for atypical coverage, doxycycline for
atypical coverage, or amoxicillin for typical bacterial coverage, depending on local resistance
patterns and patient factors. These agents effectively address the most probable etiologies of CAP.
Q3 QUESTION 3 OF 84
what to give if 1st CAP treatment doesn't work?
RESPONSE
Respiratory Fluoroquinolone if not received abx in the past 3 months
Page 2
, RATIONALE
Failure of initial community-acquired pneumonia (CAP) treatment often indicates drug-resistant
pathogens or inadequate coverage. A respiratory fluoroquinolone provides broad-spectrum
activity, including against common resistant organisms like *Streptococcus pneumoniae*, making
it a suitable second-line option when prior antibiotics are absent. This choice accounts for
potential resistance mechanisms and ensures more robust coverage.
Q4 QUESTION 4 OF 84
Mycoplasma pneumoniae
RESPONSE
atypical pneumonia; commonly seen in children
RATIONALE
This pathogen characteristically causes atypical pneumonia, distinguished by its gradual onset and
non-productive cough. It is a frequent cause of community-acquired pneumonia, particularly in
pediatric populations.
Q5 QUESTION 5 OF 84
pediatric atypical pneumonia treatment
RESPONSE
Macrolides (Erythromycin), if failed then Respiratory fluoroquinolone
RATIONALE
Atypical pneumonia in children is often caused by Mycoplasma pneumoniae or Chlamydophila
pneumoniae, necessitating treatment with macrolides like erythromycin. If initial therapy proves
ineffective, a second-line approach involves a respiratory fluoroquinolone, which offers broader
coverage against atypical pathogens.
Q6 QUESTION 6 OF 84
CAP treatment during pregnancy
Page 3
, RESPONSE
Amoxicillin, cephalosporins, or Erythromycin
RATIONALE
During pregnancy, antibiotic selection for community-acquired pneumonia (CAP) prioritizes
agents with established safety profiles. These medications are effective against common
respiratory pathogens while minimizing risks to both the mother and fetus, aligning with current
obstetric infectious disease guidelines for this population.
Q7 QUESTION 7 OF 84
Treatment of chlamydial pneumonia in infant
RESPONSE
Macrolide (Azithromycin): 500mg orally on day 1 followed by 250 mg once daily on days 2-5
RATIONALE
Macrolides, such as azithromycin, are the first-line treatment for *Chlamydia trachomatis*
pneumonia in infants due to their efficacy and favorable dosing profile. The prescribed regimen
targets the intracellular bacteria, eradicating the infection and preventing complications.
Q8 QUESTION 8 OF 84
When to use broad/empiric spectrum antibiotics?
RESPONSE
Before cultures are resulted/ critically ill patient after first culture obtained, based on NP
knowledge of patient history, local susceptibility/geographic location
RATIONALE
Empiric antibiotic therapy is initiated before definitive pathogen identification to address life-
threatening infections. This approach relies on clinical suspicion, patient history, and knowledge of
local resistance patterns to select the most appropriate broad-spectrum agent, particularly in
critically ill individuals. Therapy is then narrowed once culture and sensitivity results are available.
Page 4
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 566 Midterm Exam
2026/2027 | Advanced
Nursing Questions &
Answers | Exam-Focused
Review (Rationales)
Verified Answers Exam Ready With Rationales 84 QUESTIONS
DOCUMENT OVERVIEW
This document provides 84 questions with correct answers and detailed rationales, serving
as an exam-focused review for advanced nursing. It covers a broad range of clinical nursing
topics, offering students a comprehensive tool for study, course review, and certification
preparation.
TOPICS
Respiratory Infections & Treatments Q1–Q18
Antibiotic Pharmacology & Patient Education Q19–Q35
Antifungal & Anthelmintic Agents Q36–Q42
HIV & Antiretroviral Therapy Q43–Q49
Dermatology & Ophthalmic Agents Q50–Q67
Weight Management Pharmacology Q68–Q84
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 84
Common CAP pathogens
RESPONSE
S. Pneumoniae (most common)
H. Influenzae (smokers/COPD)
P. Aeruginosa (CF)
RATIONALE
Community-acquired pneumonia (CAP) is most frequently caused by *Streptococcus
pneumoniae*. *Haemophilus influenzae* is a common pathogen in individuals with underlying
respiratory conditions like COPD or smoking history, while *Pseudomonas aeruginosa* is a
significant cause in patients with cystic fibrosis. The findings in the stem align with this choice,
making it the best-supported option.
Q2 QUESTION 2 OF 84
CAP first line treatment
RESPONSE
Macrolides, Doxycyline, Amoxicillin
RATIONALE
Community-acquired pneumonia (CAP) first-line pharmacotherapy targets common bacterial
pathogens. Empiric treatment often includes macrolides for atypical coverage, doxycycline for
atypical coverage, or amoxicillin for typical bacterial coverage, depending on local resistance
patterns and patient factors. These agents effectively address the most probable etiologies of CAP.
Q3 QUESTION 3 OF 84
what to give if 1st CAP treatment doesn't work?
RESPONSE
Respiratory Fluoroquinolone if not received abx in the past 3 months
Page 2
, RATIONALE
Failure of initial community-acquired pneumonia (CAP) treatment often indicates drug-resistant
pathogens or inadequate coverage. A respiratory fluoroquinolone provides broad-spectrum
activity, including against common resistant organisms like *Streptococcus pneumoniae*, making
it a suitable second-line option when prior antibiotics are absent. This choice accounts for
potential resistance mechanisms and ensures more robust coverage.
Q4 QUESTION 4 OF 84
Mycoplasma pneumoniae
RESPONSE
atypical pneumonia; commonly seen in children
RATIONALE
This pathogen characteristically causes atypical pneumonia, distinguished by its gradual onset and
non-productive cough. It is a frequent cause of community-acquired pneumonia, particularly in
pediatric populations.
Q5 QUESTION 5 OF 84
pediatric atypical pneumonia treatment
RESPONSE
Macrolides (Erythromycin), if failed then Respiratory fluoroquinolone
RATIONALE
Atypical pneumonia in children is often caused by Mycoplasma pneumoniae or Chlamydophila
pneumoniae, necessitating treatment with macrolides like erythromycin. If initial therapy proves
ineffective, a second-line approach involves a respiratory fluoroquinolone, which offers broader
coverage against atypical pathogens.
Q6 QUESTION 6 OF 84
CAP treatment during pregnancy
Page 3
, RESPONSE
Amoxicillin, cephalosporins, or Erythromycin
RATIONALE
During pregnancy, antibiotic selection for community-acquired pneumonia (CAP) prioritizes
agents with established safety profiles. These medications are effective against common
respiratory pathogens while minimizing risks to both the mother and fetus, aligning with current
obstetric infectious disease guidelines for this population.
Q7 QUESTION 7 OF 84
Treatment of chlamydial pneumonia in infant
RESPONSE
Macrolide (Azithromycin): 500mg orally on day 1 followed by 250 mg once daily on days 2-5
RATIONALE
Macrolides, such as azithromycin, are the first-line treatment for *Chlamydia trachomatis*
pneumonia in infants due to their efficacy and favorable dosing profile. The prescribed regimen
targets the intracellular bacteria, eradicating the infection and preventing complications.
Q8 QUESTION 8 OF 84
When to use broad/empiric spectrum antibiotics?
RESPONSE
Before cultures are resulted/ critically ill patient after first culture obtained, based on NP
knowledge of patient history, local susceptibility/geographic location
RATIONALE
Empiric antibiotic therapy is initiated before definitive pathogen identification to address life-
threatening infections. This approach relies on clinical suspicion, patient history, and knowledge of
local resistance patterns to select the most appropriate broad-spectrum agent, particularly in
critically ill individuals. Therapy is then narrowed once culture and sensitivity results are available.
Page 4
